Transfecting Edit-R™ Cas9 mRNA with Synthetic Guide RNA in Cultured Mammalian Cells
- Horizon Team 1
- 1 - Horizon/Perkin Elmer
Jul 28, 2021
Abstract
This is an abbreviated protocol for transfecting Edit-R™ Cas9 mRNA (Cat #CAS11195, #CAS11859, or #CAS11860) with synthetic guide RNA into cultured mammalian cells using DharmaFECT™ Duo transfection reagent (Cat #T-2010-xx). Synthetic guide RNA can be either synthetic single guide RNA, or synthetic crRNA complexed with tracrRNA. The protocol is intended for use after optimization for your cell line has been completed.
Introduction
The CRISPR-associated enzyme Cas9 is an RNA-guided endonuclease that requires a guide RNA for genomic DNA target recognition and generation of DNA double-strand breaks (DSB).
Cas9 nuclease mRNA expresses a human codon-optimized version of the S. pyogenes Cas9 nuclease gene with two nuclear localization signals (NLS). The Cas9 nuclease complexes with a guide RNA for genomic DNA target recognition and cleavage, enabling researchers to perform genome engineering experiments in a completely DNA-free manner.
Cas9 Nuclease mRNA is available in a form that co-expresses either mKate2 or EGFP for transfection optimization or enrichment using fluorescence-activated cell sorting (FACS).
Reagents and Equipment
Edit-R™ Cas9 mRNA (Cat #CAS11195, #CAS11859, or #CAS11860)
DharmaFECT™ Duo transfection reagent (Cat #T-2010-xx)
Procedure
Time Taken
2 daysRelated Content
-
Primer
Orthogonal Validation in Genome Editing Discovery Work -
Primer
Solvent Precipitation Method Increases Protein Recovery for Proteomics -
Protocol
High-Throughput In Vitro, Ex Vivo, and In Vivo Screen of Adeno-Associated Virus Vectors Based on Physical and Functional Transduction -
Protocol
Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells -
Protocol
Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the βA(T87Q)-Globin Gene - More